Cyclerion Therapeutics, Inc.

CYCNSEC EDGAR

Pharmaceutical Preparations(MA)CIK: 1755237

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	—	—	$4.5M
Research and Development Expense	$1.5M	$6.0M	$37.6M	$56.4M	$95.1M
Operating Expenses	$2.4M	$18.8M	$59.1M	$83.6M	$129.5M
Operating Income (Loss)	-$13.0M	-$18.5M	-$55.2M	-$81.3M	-$125.0M
Nonoperating Income (Expense)	$358.0K	$294.0K	-$16.0K	$588.0K	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$5.3M	-$44.1M	-$51.6M	-$122.4M	-$122.4M
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$13.4M	$18.1M	$59.3M	$115.4M	$186.5M
Assets, Current	$8.0M	$14.8M	$55.5M	$58.5M	$101.2M
Cash and Cash Equivalents, at Carrying Value	$7.6M	$13.4M	$54.0M	$54.4M	$94.9M
Accounts Receivable, after Allowance for Credit Loss, Current	$0.00	$96.0K	$100.0K	$0.00	—
Liabilities, Current	$2.1M	$7.6M	$11.1M	$17.0M	$18.2M
Accounts Payable, Current	$1.2M	$3.0M	$1.8M	$1.1M	$3.2M
Stockholders' Equity Attributable to Parent	$10.5M	$48.2M	$59.5M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$21.2M	-$40.6M	-$36.5M	-$72.5M	-$102.2M
Net Cash Provided by (Used in) Investing Activities	$10.4M	$0.00	$1.5M	$18.0K	-$6.7M
Net Cash Provided by (Used in) Financing Activities	$5.0M	$29.0K	$30.8M	$28.1M	$211.6M
Payments to Acquire Property, Plant, and Equipment	—	—	$7.0K	$1.5M	$6.9M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)